1 min read
Abivax Shares Fall About 9% After Scorpion Research Short Report
The report criticized the clinical development of obefazimod, Abivax’s ulcerative colitis candidate. Scorpion Research disclosed a short position in the company.

Abivax shares closed down about 9% Friday, Nov. 20, 2026, after Scorpion Research issued a short report criticizing the clinical development of the company’s ulcerative colitis candidate, obefazimod.
Scorpion Research disclosed that it holds a short position in Abivax. The report’s criticism was directed at obefazimod’s clinical development.